Wall Street beckons for tearaway Australian biotech Telix Pharmaceuticals, one of the ASX’s best-performed companies over the past five years, and it is hard to see how the company’s board can resist.

The $3 billion Telix needs access to a bigger pool of biotech investors if it is to graduate from niche Aussie business success story to a serious global player that can compete with the big pharmaceutical companies coming for its patch.